1
|
Govaere O, Petz M, Wouters J, Vandewynckel YP, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017; 36:6605-6616. [PMID: 28783171 PMCID: PMC5702717 DOI: 10.1038/onc.2017.260] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 05/30/2017] [Accepted: 06/08/2017] [Indexed: 02/07/2023]
Abstract
Human hepatocellular carcinomas (HCCs) expressing the biliary/hepatic progenitor cell marker keratin 19 (K19) have been linked with a poor prognosis and exhibit an increase in platelet-derived growth factor receptor α (PDGFRα) and laminin beta 1 (LAMB1) expression. PDGFRα has been reported to induce de novo synthesis of LAMB1 protein in a Sjogren syndrome antigen B (La/SSB)-dependent manner in a murine metastasis model. However, the role of this cascade in human HCC remains unclear. This study focused on the functional role of the PDGFRα-La/SSB-LAMB1 pathway and its molecular link to K19 expression in human HCC. In surgical HCC specimens from a cohort of 136 patients, PDGFRα expression correlated with K19 expression, microvascular invasion and metastatic spread. In addition, PDGFRα expression in pre-operative needle biopsy specimens predicted poor overall survival during a 5-year follow-up period. Consecutive histological staining demonstrated that the signaling components of the PDGFRα-La/SSB-LAMB1 pathway were strongly expressed at the invasive front. K19-positive HCC cells displayed high levels of α2β1 integrin (ITG) receptor, both in vitro and in vivo. In vitro activation of PDGFRα signaling triggered the translocation of nuclear La/SSB into the cytoplasm, enhanced the protein synthesis of LAMB1 by activating its internal ribosome entry site, which in turn led to increased secretion of laminin-111. This effect was abrogated by the PDGFRα-specific inhibitor crenolanib. Importantly LAMB1 stimulated ITG-dependent focal adhesion kinase/Src proto-oncogene non-receptor tyrosine kinase signaling. It also promoted the ITG-specific downstream target Rho-associated coiled-coil containing protein kinase 2, induced K19 expression in an autocrine manner, invadopodia formation and cell invasion. Finally, we showed that the knockdown of LAMB1 or K19 in subcutaneous xenograft mouse models resulted in significant loss of cells invading the surrounding stromal tissue and reduced HepG2 colonization into lung and liver after tail vein injection. The PDGFRα-LAMB1 pathway supports tumor progression at the invasive front of human HCC through K19 expression.
Collapse
Affiliation(s)
- O Govaere
- Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
- Liver Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
| | - M Petz
- Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - J Wouters
- Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
| | - Y-P Vandewynckel
- Department of Hepatology and Gastroenterology, Ghent University, Ghent, Belgium
| | - E J Scott
- Liver Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
| | - B Topal
- Department of Abdominal Surgery, KU Leuven and University Hospitals Leuven, Leuven, Belgium
| | - F Nevens
- Department of Hepatology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
| | - C Verslype
- Department of Hepatology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
| | - Q M Anstee
- Liver Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle-upon-Tyne, UK
| | - H Van Vlierberghe
- Department of Hepatology and Gastroenterology, Ghent University, Ghent, Belgium
| | - W Mikulits
- Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - T Roskams
- Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
2
|
Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Floris G, Van den Eynde K, Schoffski P, Smeets A, Neven P, Lambrechts D, Sotiriou C, Wildiers H. Abstract P4-03-01: The footprint of the aging stroma in older breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-03-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Tumoral masses are not only composed of malignant cells, but also enclose a more or less ample stromal micromilieu, which has been shown to influence the cancer cell behaviour. As aging induces accumulation of senescent cells in the body, this micromilieu is thought to be different in cancers occurring in old patients compared to the younger counterparts. More specifically, senescence-related fibroblastic features, such as the Senescence Associated Secretory Profile (SASP) and the induction of Autophagy, are suspected to stimulate tumor growth and progression.
Materials and Methods: We compared gene expression profiles in stromal fields of breast carcinomas by performing laser capture microdissection of the cancer-associated stroma from 8 old (≥80 years at diagnosis) and 9 young (< 45 years at diagnosis) triple negative breast cancer patients. Gene expression data were obtained by microarray analysis (Affymetrix). Differential gene expression and Gene Set Enrichment Analysis (GSEA) were performed.
Results: Differential gene expression analysis showed higher growth-, dedifferentiation- and migration- promoting gene expression in the stromal samples of older vs younger patients. GSEA confirmed the presence of a SASP, as well as the presence of Autophagy in the the stroma of older patients.
Conclusion: We provide the first evidence in humans that older age at diagnosis is associated with a different stromal micromilieu in breast cancers. The SASP and the presence of Autophagy appear to be important age-induced stromal features.Introduction: Tumoral masses are not only composed of malignant cells, but also enclose a more or less ample stromal micromilieu, which has been shown to influence the cancer cell behaviour. As aging induces accumulation of senescent cells in the body, this micromilieu is thought to be different in cancers occurring in old patients compared to the younger counterparts. More specifically, senescence-related fibroblastic features, such as the Senescence Associated Secretory Profile (SASP) and the induction of Autophagy, are suspected to stimulate tumor growth and progression.
Materials and Methods: We compared gene expression profiles in stromal fields of breast carcinomas by performing laser capture microdissection of the cancer-associated stroma from 8 old (≥80 years at diagnosis) and 9 young (< 45 years at diagnosis) triple negative breast cancer patients. Gene expression data were obtained by microarray analysis (Affymetrix). Differential gene expression and Gene Set Enrichment Analysis (GSEA) were performed.
Results: Differential gene expression analysis showed higher growth-, dedifferentiation- and migration- promoting gene expression in the stromal samples of older vs younger patients. GSEA confirmed the presence of a SASP, as well as the presence of Autophagy in the the stroma of older patients.
Conclusion: We provide the first evidence in humans that older age at diagnosis is associated with a different stromal micromilieu in breast cancers. The SASP and the presence of Autophagy appear to be important age-induced stromal features.
Citation Format: Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Floris G, Van den Eynde K, Schoffski P, Smeets A, Neven P, Lambrechts D, Sotiriou C, Wildiers H. The footprint of the aging stroma in older breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-01.
Collapse
Affiliation(s)
- B Brouwers
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - D Fumagalli
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - S Brohee
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - S Hatse
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - O Govaere
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - G Floris
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - K Van den Eynde
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - P Schoffski
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - A Smeets
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - P Neven
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - D Lambrechts
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - C Sotiriou
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| | - H Wildiers
- Laboratory of Experimental Oncology, KU Leuven & University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospitals Leuven, Leuven, Belgium; Multidisciplinary Breast Canter, University Hospitals Leuven, Leuven, Belgium; Vesalius Research Center (VRC), VIB, KU Leuven, Leuven, Belgium
| |
Collapse
|